Netherlands· NL-e829f78d5f46
Pradaxa 30 mg omhuld granulaat
A dabigatran etexilate product containing dabigatranetexilaatmesilaat, registered in Netherlands by Boehringer Ingelheim International GmbH. The same ATC class is registered in 16 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Dabigatran etexilate is registered in 16 of 19 countries.
Countries holding a registration under ATC B01AE07 (dabigatran etexilate), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 10 of them publish a price we can compare per daily dose
Dabigatran etexilate · ATC B01AE07
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of dabigatran etexilate costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Dabigatran etexilate · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$3.16
- IT Italy$2.17
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- DABIGATRANETEXILAATMESILAAT
- Manufacturer
- Boehringer Ingelheim International GmbH
- Country
- Netherlands (NL)
- ATC code
- B01AE07
- ATC class
- Dabigatran etexilate
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/08/442
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
47 interactions on record for dabigatran etexilate.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Dabigatran etexilate · interactions on record
47 records
47 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under B01AE07
Dabigatran etexilate, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d513aee0-9048-4738-8d45-41f8127fdf94 GET /v1/drugs/d513aee0-9048-4738-8d45-41f8127fdf94?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Omhuld granulaat",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Dabigatran Etexilate",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp125787",
"excipients": [
"ARABISCHE GOM (E 414)",
"DIMETICON (E 900)",
"HYPROLOSE (E 463)",
"HYPROMELLOSE 2910 (3 - 15 mPa.s) (E 464)",
"TALK (E 553b)",
"WIJNSTEENZUUR, (L (+) Vorm) (E 334)"
],
"substances": [
"DABIGATRANETEXILAATMESILAAT"
],
"leaflet_url": null,
"authorised_at": "2021/01/11",
"procedure_number": "EMEA/H/C/000829",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/08/442",
"additional_monitoring": "N"
}See everything about dabigatran etexilate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.